Urinary incontinence due to neurogenic detrusor overactivity MedDRA version: 9.1 Level: LLT Classification code 10029279 Term: Neurogenic bladder
Conditions
Sponsors
Allergan Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1] Patient is male or female, aged 18 to 80 years old [2] Patient weighs = 50 kg (110 lb) [3] Written informed consent has been obtained [4] Written Authorization for Use and Release of Health and Research Study Information (US sites only) has been obtained [5] Written Data Protection Consent (European sites only) has been obtained [6] Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable [7] Patient has urinary incontinence as a result of neurogenic detrusor overactivity for a period of at least 3 months prior to screening as a result of spinal cord injury or multiple sclerosis, determined by documented patient history. In addition [7a] Spinal cord injury patients must have a stable neurological injury level at T1 or below (cervical injuries are excluded) occurring = 6 months prior to screening; [7b] Multiple sclerosis patients must be clinically stable in the investigator’s opinion, for = 3 months prior to screening and have an Expanded Disability Status Scale (EDSS) score = 6.5. [8] Patient has detrusor overactivity (defined as a phasic rise in bladder pressure during the filling phase determined by urodynamics) demonstrated during the screening period or Day 1 (prior to randomization) [9] Patient is able to complete study requirements including electronic bladder diary completion and attend all study visits (telephone and clinic), in the opinion of the investigator [10] Patient has not been adequately managed with one or more anticholinergics for their urinary incontinence, in the opinion of the investigator. Not adequately managed is defined as an inadequate response or intolerable side effects after at least one month of anticholinergic therapy on an optimized dose [11] For patients taking anticholinergic medication for their neurogenic overactive bladder, dose is stable and patient is willing to maintain same dosing during study participation [12] Patient has a negative pregnancy result if female and of childbearing potential The following criteria are also required for entry into the study at Randomization/Day 1: [13] Patient experiences = 14 episodes of urinary incontinence per week with no more than 2 incontinent-free days, determined by completion of patient bladder diary during the screening period [14] Patient currently uses or is willing to use clean intermittent catheterization (CIC) to empty the bladder (indwelling catheter is not permitted). Patients currently on CIC should be willing to maintain an established CIC frequency throughout the study. Caregiver may perform CIC [15] Patients with a negative urine culture result must take an antibiotic medication for 3 days immediately prior to Randomization/Day 1 and agree to continue antibiotic medication for at least 3 days following treatment. Patients with a positive urine culture result indicating urinary tract infection (UTI), must take an antibiotic to which the identified organism is sensitive for at least 5 days immediately prior to Randomization/Day 1 and continue for 3 days following the procedure (or longer as needed) and patient is asymptomatic for UTI on day of treatment. A UTI is defined as either a positive urine culture result with a bacteriuria count of > 10^5 CFU/mL conjoint with a leukocyturia > 5/hpf at screening or a positive urine culture that, in the investigator’s opinion, requires antibiotic therapy Are the trial subjects under 18? no Number of subjects for this age
Exclusion criteria
Exclusion criteria: [1] Patient has history or evidence of any pelvic or urological abnormalities including but not limited to the following: [1a] elevated serum creatinine > 2 times the upper limit of normal (reference range) [1b] history of or current hematuria, [1ba] if the hematuria is determined to be due to a pathologic condition or [1bb] is uninvestigated [1c] interstitial cystitis in the opinion of the investigator [1d] bladder stones within 6 months of screening [1e] surgery or bladder disease other than detrusor overactivity that may impact bladder function with the exception of surgeries for bladder stones (> 6 months) and stress incontinence, uterine prolapse, rectocele, or cystocele (>1 year) from screening [2] Patient has had previous or current botulinum toxin therapy of any serotype for any urological condition or, treatment within 3 months of Randomization/Day 1 for any other condition or use. [3] Patient has been immunized for any botulinum toxin serotype. [4] Patient discontinued anticholinergic medication for overactive bladder 3000 mL of urine determined by completion of patient bladder diary collected over one consecutive 24 hour period during the 7 day diary collection period prior to Randomization/Day1. [9] Patient has a post void residual volume above 150 mL for patients who micturate or have a mixed catheterization/micturition pattern. [10] Patient has an active genital infection, other than genital warts, either concurrently or within 4 weeks prior to screening. [11] Patient uses any anti-platelet or anticoagulant therapy or is using medications with anticoagulative effects within 3 days prior to treatment. Some medications may need to be withheld for > 3 days per clinical judgment of the investigator. [12] Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diatheses. [13] Patient has had concurrent treatment or treatment within 6 months of Randomization/Day 1 with capsaicin or resiniferatoxin. [14] Patient is currently using or plans to use an implanted or non-implantable electrostimulation/neuromodulation device for treatment of overactive bladder. [15] Patient has a known allergy or sensitivity to any components of the study medication, anesthetics or antibiotics or any other products associated with the treatment and general study procedures. [16] Patient has any medical condition that may put the patient at increased risk with exposure to BOTOX® including diagnosed myasthenia gravis, Eaton-Lambert syndrome or amyotrophic lateral sclerosis. [17] Patient is female and pregnant, nursing or planning a pregnancy during the study, or of childbearing potential and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the safety and efficacy of each of 2 dosages of BOTOX® (200 U or 300 U) compared to placebo injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have not been adequately managed with anticholinergic therapy.;Secondary Objective: [1] Patients will also undergo a procedure called urodynamics, which measures various parameters including, but not limited to, the volume the bladder can hold before it contracts and the pressure in the bladder before and during a contraction. [2] Health Outcomes measures assessed by questionnaires completed by the patient. These include an Incontinence Quality of Life score. [3] For those patients who respond, how long the effect of the treatment lasts. [4] Number of times a patient empties their bladder either by using a catheter or going to the toilet normally. [5] Total amount of urine voided over a 24 hr period as recorded by the patient in the bladder diary.;Primary end point(s): The primary efficacy assessment is the number of episodes of urinary incontinence as recorded by patient bladder diary during the 7 days prior to each study visit (telephone and clinic). Primary timepoint is at Week 6 following the first treatment | — |
Countries
France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom
Outcome results
None listed